Immune Response News and Research

RSS

Study: HIV superinfection may be more common than previously believed

Human immunodeficiency virus (HIV) superinfection may be as common as initial HIV infection and is not limited to high risk-populations, according to a new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the National Institute of Allergy and Infectious Diseases.

8 Jun 2012

Lung changes in association with ACPA status are a primary manifestation of RA

A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, shows that lung changes in association with anti-citrullinated protein autoantibody (ACPA) status are a primary manifestation of rheumatoid arthritis (RA).

8 Jun 2012

HIV superinfection may be more frequent among general population of Uganda

HIV superinfection, when a person with HIV could acquire a second, new strain of HIV, may occur as often as initial HIV infection in the general population in Uganda, a study suggests.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Targeting stem cells might be more effective in treating vascular disease

One of the top suspects behind killer vascular diseases is the victim of mistaken identity, according to researchers from the University of California, Berkeley, who used genetic tracing to help hunt down the real culprit.

7 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

The biopharmaceutical company Antisense Pharma today presents trabedersen complete data from its clinical Phase I/II study in patients with advanced pancreatic cancer, malignant melanoma or colorectal cancer at the international cancer congress ASCO 2012 in Chicago, USA.

5 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

NYUCD receives NIH grant for ‘Biomarkers of Periodontal Disease Progression’ project

New York University College of Dentistry has been selected as one of five institutions that are sharing a $20.7 million grant from the National Institute of Dental and Craniofacial Research (NIH) to the Forsyth Institute to find new ways to diagnose and fight periodontal disease.

1 Jun 2012

Scientists discover SL9266 'switch' in the Hepatitis C virus

Scientists have discovered a 'switch' in the Hepatitis C virus which could be used as a target for new kinds of drug treatment.

1 Jun 2012

Researchers uncover potential new way to regulate the body's natural immune response

Australian researchers have uncovered a potential new way to regulate the body's natural immune response, offering hope of a simple and effective new treatment for auto-immune diseases.

1 Jun 2012

Einstein receives NIH grant to create new vaccine against TB

The National Institutes of Health (NIH) has awarded researchers at Albert Einstein College of Medicine at Yeshiva University a five-year, $5.9 million grant to develop a new vaccine against tuberculosis (TB), including the toughest-to-treat forms of the disease known as multi drug-resistant and extensively drug-resistant. The grant will build on a new approach to TB vaccine design that is based on genetically altered Mycobacterium smegmatis, which is closely related to the bacterial species (Mycobacterium tuberculosis) that causes TB in humans.

1 Jun 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

New diagnostic approach for Lyme disease

George Mason University researchers can find out if a tick bite means Lyme disease well before the bite victim begins to show symptoms.

25 May 2012

Study sheds light on role of microglia in the normal brain

Researchers have shown in mice how immune cells in the brain target and remove unused connections between brain cells during normal development. This research, supported by the National Institutes of Health, sheds light on how brain activity influences brain development, and highlights the newly found importance of the immune system in how the brain is wired, as well as how the brain forms new connections throughout life in response to change.

24 May 2012

PTH boosts AMPs to fend off infection-causing microbes

Antimicrobial peptides (AMPs) are molecules produced in the skin to fend off infection-causing microbes. Vitamin D has been credited with a role in their production and in the body's overall immune response, but scientists at the University of California, San Diego School of Medicine say a hormone previously associated only with maintaining calcium homeostasis and bone health is also critical, boosting AMP expression when dietary vitamin D levels are inadequate.

24 May 2012

Panel of HuCAL Anti-Drug Antibodies to be launched by AbD Serotec

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that its division for research and diagnostic antibodies, AbD Serotec, will launch a series of novel anti-drug antibodies (ADAs) to strengthen its position as a leading provider of diagnostic reagents.

23 May 2012

B cells in breast milk can produce HIV-neutralizing antibodies

Antibodies that help to stop the HIV virus have been found in breast milk. Researchers at Duke University Medical Center isolated the antibodies from immune cells called B cells in the breast milk of infected mothers in Malawi, and showed that the B cells in breast milk can generate neutralizing antibodies that may inhibit the virus that causes AIDS.

23 May 2012

Thermo Scientific Watson LIMS offers enhanced functionality for bioanalytical laboratories

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific Watson LIMS (laboratory information management system) offers enhanced functionality for large molecule bioanalysis in pharmaceutical and contract research organization (CRO) laboratories.

From Thermo Fisher Scientific Inc. 22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012